Premium
The pipeline of antiviral T‐cell therapy: what's in the clinic and undergoing development
Author(s) -
Fatic Alyssa,
Zhang Nan,
Keller Michael D.,
Hanley Patrick J.
Publication year - 2020
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.15501
Subject(s) - virology , virus , herpes simplex virus , cytomegalovirus , varicella zoster virus , medicine , hematopoietic stem cell transplantation , immunology , herpesviridae , transplantation , viral disease , surgery
KEY IDEAS Virus‐specific T cells allow targeting of multiple pathogens in patients after hematopoietic stem cell transplantation and have demonstrated potential efficacy for cytomegalovirus, Epstein–Barr Virus, and adenovirus. Novel targets may include BK virus, JC virus, varicella zoster virus, human herpesvirus 6, Aspergillus, human parainfluenza virus‐3, herpes simplex virus Type I, Zika virus, and mycobacteria. Generation of patient‐specific products and third‐party products may expand feasibility of therapy.